Agios Pharmaceuticals Raised $294 Million to Fight Cancer and Rare Genetic Diseases: What It Means for Investors
The cash will help the biotech get to profitability.
AGIOS PHARMACEUTICALS INC
The cash will help the biotech get to profitability.
AGIO earnings call for the period ending September 30, 2019.
AGIO earnings call for the period ending June 30, 2019.
AGIO earnings call for the period ending March 31, 2019.
AGIO earnings call for the period ending December 31, 2018.
If GlaxoSmithKline's recent splurge signals a new round of acquisitions, these stocks could be next.
On a positive day for the market, these stocks outperformed. Find out why.
Short-sellers have piled on Agios, Insys, Intercept, Lexicon, and Myriad Genetics. But are they wrong?
Funding isn't a big concern for these three drug developers.
It was a roller-coaster year for investors in the clinical-stage biotech. Here's a review of the year's key headlines that caused shares to drop.